摘要
目的:评价唑来膦酸联合盐酸埃克替尼治疗肺癌骨转移患者临床效果,为临床治疗提供基础资料。方法:选取2012年7月-2013年8月在肿瘤内科住院治疗的肺癌骨转移患者96例,作为联合用药组,同时,选取60例作为奥施康定组,联合用药组给予口服盐酸埃克替尼片和静脉滴注唑来膦酸,奥施康定组给予口服盐酸羟考酮缓释片治疗。采用NRS法评价镇痛效果,利用EORTC QLQ-C30量表评估患者生活质量,并利用MRI骨扫描评估骨转移病灶修复效果,并记录不良反应情况。结果:治疗后,联合用药组患者疼痛评分为(3.4±1.9)分,奥施康定组患者疼痛评分为(3.1±1.7)分,2组患者疼痛评分差异无统计学意义(P>0.05);联合用药组患者生活质量总评分高于奥施康定组,差异具有统计学意义(P<0.05),各维度评分中,联合用药组患者身体功能、心理状态、社会功能和健康评分均高于奥施康定组,差异均具有统计学意义(P<0.05);联合用药组患者转移灶14例完全缓解,22例部分缓解,34例稳定,26例无效,总有效率为72.9%,显著高于奥施康定组的51.7%(P<0.05);联合用药组患者不良反应总发生率为35.4%,显著低于奥施康定组的61.7%,差异具体统计学意义(χ2=10.260,P=0.001)。结论:唑来膦酸联合盐酸埃克替尼用于治疗肺癌骨转移患者,可以有效减轻疼痛、提高患者生活质量,同时,联合用药使用方便、效果显著、不良反应发生率较低,值得进一步在临床推广。
OBJIETIVE To investigate the clinical efficacy of treatment of zoledronic acid combined with icotinib hydrochlo- ric in bone metastasis of lung cancer, and to provide basic data for the clinical treatment. METHODS 96 cases of patients with lung cancer bone metastasis in the department of medical oncology were selected from July 2012 to August 2013 at the First Af- filiated Hospital of Zhengzhou University, as a combined treatment group. Meanwhile, 60 cases were selected as OxyContin group. Combined treatment group was given oral icotinib hydrochloride tablets and intravenous zoledronic acid. OxyContin group was given oral oxycodone hydrochloride extended release tablets. NRS assay was used to evaluate the effect of analgesia. The quality of life of patient was evaluated by using the EORTC QLQ-C30 scale. Bone metastatic lesion repair effect was as- sessed by MRI bone scan. Adverse reactions were noted. RESULTS After treatment, pain score of patients in combined treat- ment group was （3. 4±1. 9）, and in OxyContin group was （3. 1±1.7）, the pain scores between the two groups were not sta- tistically significant （t = 0. 861, P〈0. 05）. The overall quality of life scores of patients in combined group were higher than OxyContin group, the difference was statistically significant （P〈0. 05）. Of each dimension score, physical function, psycho- logical state, social function and health in combined group were higher than OxyContin group, the differences were all statisti eally significant （P〈0. 05）. The metastases in the combined group, seven cases were complete remission, 22 cases were partial remission, 34 cases were stable, 26 cases were in effective, the total effective rate was 72.9%, which was significantly higher than 51.7% of OxyContin group （P〈0. 05）. The overall incidence of adverse reactions of patients in combined treatment group was 35.4%, which was significantly lower than 61.7% of OxyContin group, the difference was statistically significant （χ2 = 10. 260, P = 0. 001）. CONCLUSION Zoledronic acid combined icotinib hydrochloride for the treatment of lung cancer patients with bone metastases, could effectivdy relieve pain and improve the quality of life of patients. Simultaneously, it was easy to use, the effect was significant, and had fewer complications. It was worthy of further clinical practice.
出处
《中国医院药学杂志》
CAS
CSCD
北大核心
2014年第13期1096-1099,共4页
Chinese Journal of Hospital Pharmacy
基金
常州四药临床药学科研基金(编号:CZSYJJ13001)
关键词
唑来膦酸
盐酸埃克替尼
联合治疗
奥施康定
肺癌骨转移
zoledronic acid
icotinib hydrochloride
combined treatment
OxyContin
lung cancer bone metastasis
